We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+4.22%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.22B
AUM Growth
+$986M
Cap. Flow
+$1.27B
Cap. Flow %
17.6%
Top 10 Hldgs %
44.55%
Holding
109
New
17
Increased
12
Reduced
6
Closed
14

Top Buys

Rank Stock Value
1
CLYM
Climb Bio
CLYM
+$272M
2
CTKB icon
Cytek Biosciences
CTKB
+$226M
3
IVVD icon
Invivyd
IVVD
+$198M
4
ICVX
Icosavax, Inc. Common Stock
ICVX
+$196M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$177M

Top Sells

Rank Stock Value
1
AXSM icon
Axsome Therapeutics
AXSM
+$112M
2
NVAX icon
Novavax
NVAX
+$102M
3
CRIS icon
Curis
CRIS
+$57.6M
4
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$56.4M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$51.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.06%
2 Financials 0.62%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BOLT icon
51
Bolt Biotherapeutics
BOLT
$7.65M
$30.1M 0.42%
118,916
– –
SLDB icon
52
Solid Biosciences
SLDB
$790M
$29.6M 0.41%
824,525
– –
TNGX icon
53
Tango Therapeutics
TNGX
$4.43B
$29.1M 0.4%
2,250,000
+1,000,000
+80% +$12M
KALA icon
54
KALA BIO
KALA
$15.1M
$28.5M 0.39%
4,354
– –
VRNA
55
DELISTED
Verona Pharma
VRNA
$27.9M 0.39%
5,100,000
– –
STSA
56
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$27.6M 0.38%
5,914,252
– –
AKUS
57
DELISTED
Akouos Inc
AKUS
$26.5M 0.37%
2,281,249
– –
ORTX
58
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$25.4M 0.35%
1,102,872
-128,649
-10% -$3.83M
EYPT icon
59
EyePoint Inc
EYPT
$1.04B
$23M 0.32%
2,210,506
+960,506
+77% +$9.16M
IPSC icon
60
Century Therapeutics
IPSC
$357M
$23M 0.32%
914,094
– –
BDTX icon
61
Black Diamond Therapeutics
BDTX
$99.7M
$21.9M 0.3%
2,589,904
– –
SYBX
62
DELISTED
Synlogic
SYBX
$20.3M 0.28%
+444,444
New +$20.8M
SCPH
63
DELISTED
scPharmaceuticals
SCPH
$18.2M 0.25%
2,731,170
– –
CTMX icon
64
CytomX Therapeutics
CTMX
$690M
$17.8M 0.25%
3,500,000
– –
LRMR icon
65
Larimar Therapeutics
LRMR
$413M
$17.5M 0.24%
1,515,151
– –
SPRY icon
66
ARS Pharmaceuticals
SPRY
$542M
$17.4M 0.24%
1,742,186
– –
NAUT icon
67
Nautilus Biotechnolgy
NAUT
$129M
$15M 0.21%
2,436,430
-35,000
-1% -$279K
DALS
68
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$14.7M 0.2%
+1,500,000
New +$14.8M
MIST icon
69
Milestone Pharmaceuticals
MIST
$139M
$12.8M 0.18%
2,246,503
– –
BLSA
70
DELISTED
BCLS Acquisition Corp. Class A Ordinary Shares
BLSA
$12.4M 0.17%
1,250,000
– –
ATXS
71
DELISTED
Astria Therapeutics
ATXS
$11.2M 0.15%
1,262,193
+270,883
+27% +$2.6M
ENTX icon
72
Entera Bio
ENTX
$146M
$11.1M 0.15%
2,353,000
– –
TCRX icon
73
TScan Therapeutics
TCRX
$47.3M
$10.5M 0.15%
+1,255,317
New +$11.6M
RNAM
74
DELISTED
Avidity Biosciences
RNAM
$10.4M 0.14%
+423,616
New +$9.21M
WHWK
75
Whitehawk Therapeutics
WHWK
$196M
$10.2M 0.14%
347,668
+168,114
+94% +$5.12M
1 2
3
4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, RA Capital Management held 109 positions worth $7.22B, up 16% from $6.23B the previous quarter. Its ten largest holdings account for 45% of the portfolio.

RA Capital Management deployed $1.27B of net new capital in Q3 2021, opening 17 new positions and adding to 12 existing holdings. Its largest new stake was Climb Bio: 13,150,849 shares worth $236M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Novavax, an estimated $102M trimmed.

  • RA Capital Management's largest Q3 2021 buy was Climb Bio: 13,150,849 shares worth $236M.
  • RA Capital Management added most to Ascendis Pharma A/S in Q3 2021, an estimated $79.6M increase.
  • RA Capital Management's biggest Q3 2021 reduction was Novavax, cutting an estimated $102M.
  • RA Capital Management fully exited Axsome Therapeutics in Q3 2021, selling an estimated $112M.
  • RA Capital Management's ten largest holdings make up 45% of its $7.22B portfolio in Q3 2021.
  • RA Capital Management opened 17 new positions and closed 14 in Q3 2021.
  • RA Capital Management's portfolio value rose 16% quarter-over-quarter to $7.22B.

Based on RA Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.